The use of primary mesenchymal stem cells (MSCs) is fraught with aging-related shortfalls such as limited expansion and early senescence. Human induced pluripotent stem cells (iPSCs) derived MSCs (iMSCs) comprise a useful, clinically relevant source of MSCs that circumvent these aging-associated drawbacks. The importance of this concept is manifested by the successful phase 1 clinical trial for the treatment of GvHD by Cynata Therapeutics and the National Health Service of the U.K. A phase 2 trial is planned for 2019. This trial is independent of the work carried out by Spitzhorn et al.-described below.
* This article was originally published here
